Last reviewed · How we verify

NCT07353736

Cerebral Arteriovenous Malformation With Aneurysm: Epidemiology, Clinical Features, and Prognosis

Not yet recruiting Last updated 20 January 2026
What this trial tests

trial in Cerebral Arteriovenous Malformation in 630 participants. Not yet recruiting.

Timeline
1 February 2026
Primary endpoint
30 November 2030
30 December 2030

Quick facts

Lead sponsorDuan Chuanzhi
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment630
Start date1 February 2026
Primary completion30 November 2030
Estimated completion30 December 2030
Sites1 location across China

Conditions studied

Sponsor

Duan Chuanzhi — full company profile →

Who can join

Eligibility, any sex, with Cerebral Arteriovenous Malformation or Intracranial Arterial Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a multicenter, prospective cohort study designed to assess the natural history, clinical safety and efficacy of various treatment strategies in patients with cerebral arteriovenous malformations (AVMs) and intracranial aneurysms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Duan Chuanzhi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07353736.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing